>

Press Releases

YEAR
Date Description View
08/09/18

Denali Therapeutics Reports Second Quarter 2018 Financial Results

08/07/18

Denali Therapeutics Appoints Dana Andersen, Ph.D., As Chief Technical And Manufacturing Officer

08/01/18

Denali Therapeutics Announces Positive Clinical Results From LRRK2 Inhibitor Program For Parkinson’s Disease

05/30/18

Denali Therapeutics Announces Early Exercise Of Its Option To Acquire F-Star Gamma

05/11/18

Denali Therapeutics Reports First Quarter 2018 Financial Results

03/19/18

Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors; Reports Fourth Quarter And Full Year 2017 Financial Results And Business Highlights

02/08/18

Denali Therapeutics And Lonza Pharma & Biotech Announce Exclusive Partnership To Develop And Produce Biologic Medicines

01/05/18

Takeda And Denali Therapeutics Collaborate To Develop And Commercialize Therapies For Neurodegenerative Diseases

12/20/17

Denali Therapeutics Announces Advancement And Expansion Of Its LRRK2 Inhibitor Clinical Program For Parkinson’s Disease

12/12/17

Denali Therapeutics Announces Closing Of Initial Public Offering, Including Full Exercise Of Underwriters’ Option To Purchase Additional Shares

Investors & Media Relations